Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component

J Oncol Pract. 2019 Oct;15(10):e856-e862. doi: 10.1200/JOP.19.00069. Epub 2019 Aug 29.

Abstract

Purpose: A national specialty pharmacy implemented a split-fill option within an oral oncology patient management program to reduce pharmacy costs and medication wastage resulting from early discontinuations. Payers covered dispensed medications at half-quantity intervals for each dispense up to 3 months. Proactive outreach to patients before they had used up the initial dispensed medication quantity helped assess the patient's tolerance to the new medication and adverse effects. This study compared costs for patients with a split-fill option to similar costs for patients without this option taking into account patient discontinuation rates, patient-reported adverse effects rates, estimated pharmacy costs, and potential wastage.

Methods: This retrospective cohort study included patients who were new to therapy on a split-fill medication between September 2015 and August 2017. A 1:1 greedy match algorithm was conducted using propensity variables to match patients from each cohort. Per-month discontinuation rates were determined for both split-fill and non-split-fill groups. The non-split-fill potential wastage was calculated as monthly costs for discontinuations in the following month and weighted by split-fill discontinuation rates.

Results: Of the 2,363 program patients who met selection criteria for the 11 medications, 671 patients from each group were matched. Payers with a split-fill program had significant medication savings per covered month ($2,147.60 at 1 month) and at a cumulative 6 months. Modeled wastage indicated that payers without a split-fill program could expect to save $2,646.74 monthly by using this option. Both cohorts had similar rates of adverse effects and time until first reported adverse effect.

Conclusion: In the first 6 months, the split-fill patient managed program had lower discontinuation rates, significantly reduced pharmacy costs, and reduced potential wastage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / economics
  • Cost Savings*
  • Disease Management
  • Health Care Costs*
  • Humans
  • Medical Oncology* / economics
  • Medical Oncology* / methods
  • Medication Adherence
  • Neoplasms / diagnosis
  • Neoplasms / epidemiology*
  • Neoplasms / therapy
  • Outcome Assessment, Health Care
  • Pharmaceutical Services / economics
  • Propensity Score
  • Retrospective Studies
  • Time Factors

Substances

  • Antineoplastic Agents